Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Review, H2 2016

  • ID: 3876137
  • Report
  • Region: Global
  • 97 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • F. Hoffmann-La Roche Ltd.
  • Genzyme Corporation
  • Glialogix, Inc.
  • MedDay SA
  • MORE

‘Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Review, H2 2016’, provides an overview of the Primary Progressive Multiple Sclerosis (PPMS) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Primary Progressive Multiple Sclerosis (PPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Progressive Multiple Sclerosis (PPMS) and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Primary Progressive Multiple Sclerosis (PPMS)
- The report reviews pipeline therapeutics for Primary Progressive Multiple Sclerosis (PPMS) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Primary Progressive Multiple Sclerosis (PPMS) therapeutics and enlists all their major and minor projects
- The report assesses Primary Progressive Multiple Sclerosis (PPMS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Primary Progressive Multiple Sclerosis (PPMS)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Primary Progressive Multiple Sclerosis (PPMS)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Primary Progressive Multiple Sclerosis (PPMS) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • F. Hoffmann-La Roche Ltd.
  • Genzyme Corporation
  • Glialogix, Inc.
  • MedDay SA
  • MORE

Introduction

Report Coverage

Primary Progressive Multiple Sclerosis (PPMS) Overview

Therapeutics Development

Pipeline Products for Primary Progressive Multiple Sclerosis (PPMS) - Overview

Primary Progressive Multiple Sclerosis (PPMS) - Therapeutics under Development by Companies

Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Primary Progressive Multiple Sclerosis (PPMS) - Products under Development by Companies

Primary Progressive Multiple Sclerosis (PPMS) - Companies Involved in Therapeutics Development

F. Hoffmann-La Roche Ltd.

Genzyme Corporation

Glialogix, Inc.

Kyorin Pharmaceutical Co., Ltd.

MedDay SA

Santhera Pharmaceuticals Holding AG

Teva Pharmaceutical Industries Ltd.

Primary Progressive Multiple Sclerosis (PPMS) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

biotin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GLX-1112 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GZ-402668 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IB-MS - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ibudilast - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

idebenone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

laquinimod sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

masitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ocrelizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Primary Progressive Multiple Sclerosis and Secondary Progressive Multiple Scleros - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for CNS Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Primary Progressive Multiple Sclerosis (PPMS) - Dormant Projects

Primary Progressive Multiple Sclerosis (PPMS) - Discontinued Products

Primary Progressive Multiple Sclerosis (PPMS) - Product Development Milestones

Featured News & Press Releases

Jul 13, 2016: MediciNova Announces Initiation of Interim Efficacy Analysis in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS

Jun 28, 2016: Roche’s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA

May 25, 2016: MedDay attends European Academy of Neurology 2016 and presents extension phase results of the MS-SPI trial

Apr 21, 2016: MedDay reports full data from pivotal Phase IIb/III MS-SPI / MS-ON studies with MD1003 in Multiple Sclerosis at AAN

Mar 22, 2016: FDA Grants Fast Track Designation for MediciNovas MN-166 (ibudilast) for Progressive Multiple Sclerosis

Feb 17, 2016: FDA Grants Breakthrough Therapy Designation for Genentech’s Investigational Medicine Ocrelizumab in Primary Progressive Multiple Sclerosis

Dec 01, 2015: MedDay provides update on MS-ON study of MD-1003

Oct 20, 2015: Clinical trial shows first ever positive results in treating primary progressive and relapsing multiple sclerosis

Oct 10, 2015: More Results Released from Positive Phase III Clinical Trial of Ocrelizumab in Primary Progressive MS

Apr 23, 2015: Teva and Active Biotech Announce First Patient Enrolled in Phase II Study Evaluating Laquinimod for Primary Progressive MS

Mar 04, 2015: MedDay to present Pivotal Phase III data in Progressive Multiple Sclerosis at AAN Annual Meeting

Feb 01, 2015: MN-166 (ibudilast) Progressive MS Abstract Accepted for Presentation at AAN 67th Annual Meeting in Washington, DC

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Primary Progressive Multiple Sclerosis (PPMS), H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by AB Science SA, H2 2016

Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016

Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Genzyme Corporation, H2 2016

Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Glialogix, Inc., H2 2016

Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016

Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by MedDay SA, H2 2016

Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Santhera Pharmaceuticals Holding AG, H2 2016

Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Primary Progressive Multiple Sclerosis (PPMS) - Dormant Projects, H2 2016

Primary Progressive Multiple Sclerosis (PPMS) - Discontinued Products, H2 2016 84List of Figures

Number of Products under Development for Primary Progressive Multiple Sclerosis (PPMS), H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016

Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • F. Hoffmann-La Roche Ltd.
  • Genzyme Corporation
  • Glialogix, Inc.
  • MedDay SA
  • MORE
Primary Progressive Multiple Sclerosis (PPMS) pipeline therapeutics constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies. Our latest report Primary Progressive Multiple Sclerosis (PPMS) – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Primary Progressive Multiple Sclerosis (PPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Primary Progressive Multiple Sclerosis (PPMS) Primary-progressive multiple sclerosis (PPMS) is characterized by steady worsening of neurologic functioning, without any distinct relapses or periods of remission. Symptoms include problems in speech or swallowing, visual problems, fatigue and pain, bladder and bowel difficulties. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 4, 2, 1 and 1 respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Primary Progressive Multiple Sclerosis (PPMS) and features dormant and discontinued projects. Driven by data built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
  • F. Hoffmann-La Roche Ltd.
  • Genzyme Corporation
  • Glialogix, Inc.
  • Kyorin Pharmaceutical Co., Ltd.
  • MedDay SA
  • Santhera Pharmaceuticals Holding AG
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll